BSX Stock Slumps on Cyber Incident and Flat 2027 Outlook

Boston Scientific (BSX) held its third-quarter 2026 earnings call on October 28, 2026, and the news was not good. The medical device maker revealed that an eight-day network outage from a cyber incident disrupted shipments, while it also lost market share in electrophysiology and left atrial appendage closure procedures. These issues combined to flatten sales and earnings growth through 2027.

CEO Michael Mahoney was blunt: "As a result, we believe we will be challenged to grow sales and adjusted EPS in 2027 excluding our pending acquisition of Penumbra." The stock fell 5.84% on the day, reflecting investor disappointment with the near-term outlook.

To offset margin pressure from a shifting product mix and pricing pressure in China, management is restructuring supply chains and administrative functions. The goal is to cut costs without sacrificing research funding. CFO Jonathan Monson said the efforts will "deliver sustained cost efficiencies, while allowing us to prioritize investments that support long-term growth."

Despite the near-term pain, management is betting on new products. The company is advancing pulsed-field ablation technologies and expanding cardiovascular platforms, targeting $25 billion in new market opportunities by 2030. Mahoney noted a "very strong cadence of launches in 2027, 2028" that will open new markets.

Operational recovery is already underway as inventory normalizes, and clinical trials in critical care support core franchises. Dr. Ken Stein, Chief Medical Officer, highlighted cardiogenic shock as an area of major need where mechanical circulatory support can improve outcomes. Leadership expects platform upgrades to position the company for reaccelerated earnings growth, with stabilization in 2027 and acceleration in 2028 and 2029.

The cyber incident and share losses are more than a one-off hiccup. They raise questions about Boston Scientific's operational resilience and competitive position in key markets like electrophysiology, where rivals are gaining ground. The flat growth outlook for 2027 means earnings estimates will likely be revised downward, pressuring the stock in the near term.

However, the company's restructuring efforts could improve margins and efficiency, providing a cushion. The $25 billion market opportunity by 2030 is significant, representing roughly 30% of the company's current annual revenue. If management executes on its pipeline, the long-term growth story remains intact.

The stock's 5.84% drop reflects short-term pessimism, but it also creates a potential entry point for long-term investors. The key risk is whether the company can regain lost share and navigate the cyber incident's aftermath without further disruptions.

Investors should watch for signs of operational recovery, such as inventory normalization and shipment volumes, as well as updates on the Penumbra acquisition. The company's ability to deliver on its 2027-2028 product launches will be critical to restoring investor confidence.

Overall, this is a classic case of short-term pain for long-term gain. Boston Scientific has a strong track record of innovation and a diversified portfolio, which should help it weather this storm. But the next few quarters will be telling.